Introduction
Scleroderma is treated with a combination of medications, procedures, and long-term monitoring designed to slow immune-driven tissue injury, reduce vascular dysfunction, and limit fibrosis. The main treatments include immunosuppressive and disease-modifying drugs, medications that improve blood flow and organ function, and supportive measures that address specific complications such as skin thickening, lung involvement, reflux, or kidney disease. These approaches do not cure every form of the condition, but they are used to influence the biological processes that drive inflammation, abnormal blood vessel behavior, and excessive collagen deposition. By targeting those processes, treatment aims to reduce symptoms, prevent organ damage, and preserve function.
Understanding the Treatment Goals
The treatment goals in scleroderma are shaped by the disease’s three major pathophysiologic features: immune dysregulation, vasculopathy, and fibrosis. Immune abnormalities contribute to chronic inflammation and autoantibody production. Vascular injury affects small blood vessels, leading to poor circulation, Raynaud phenomenon, digital ulcers, and organ ischemia. Fibrosis results from persistent activation of fibroblasts and excess collagen deposition in the skin and internal organs. Because these processes can occur at different rates and in different organs, treatment is individualized.
The main goals are to reduce symptoms, slow or stop progression, preserve organ function, and lower the risk of severe complications. In a patient with primarily skin disease, treatment may focus on limiting skin tightening and maintaining mobility. In someone with lung, kidney, gastrointestinal, or cardiac involvement, the priority is preventing irreversible structural damage in those organs. Treatment decisions are therefore guided by which biological processes are most active and which organs are threatened.
Common Medical Treatments
Immunosuppressive therapy is commonly used when scleroderma shows active inflammatory or progressive fibrotic features. Drugs such as mycophenolate mofetil, methotrexate, cyclophosphamide, and in some settings azathioprine are used to reduce immune activation. These medications work by suppressing lymphocyte proliferation, reducing inflammatory signaling, and limiting the downstream activation of fibroblasts that produce collagen. Mycophenolate is often used for skin and lung disease because it can dampen the immune processes that help sustain fibrosis. Methotrexate is more often used for inflammatory skin and joint involvement. Cyclophosphamide, a stronger cytotoxic agent, can be used for more aggressive organ disease, particularly interstitial lung disease, because it broadly suppresses the immune response that contributes to progression.
Biologic and targeted therapies are used in selected patients when standard immunosuppression is insufficient or when a specific pathway is being targeted. Rituximab depletes B cells, which can reduce autoantibody production and inflammatory signaling linked to tissue injury. Tocilizumab blocks interleukin-6 signaling, a pathway associated with inflammation and fibroblast activation. These treatments are intended to interrupt immune mediators that help maintain the disease process, particularly in patients with progressive skin or lung involvement.
Antifibrotic treatment may be used, especially when the lungs are involved. Nintedanib slows the decline in lung function in scleroderma-associated interstitial lung disease by inhibiting multiple tyrosine kinase pathways involved in fibroblast signaling, migration, and extracellular matrix production. Rather than reversing fibrosis already present, it aims to slow the biologic mechanisms that drive ongoing scarring. This is especially important because once lung tissue becomes heavily fibrotic, normal gas exchange becomes increasingly impaired.
Vasodilator therapy is used to treat the vasculopathy that underlies Raynaud phenomenon, digital ischemia, and some forms of pulmonary arterial hypertension. Calcium channel blockers such as nifedipine relax vascular smooth muscle, reduce vasospasm, and improve peripheral blood flow. Phosphodiesterase-5 inhibitors such as sildenafil enhance nitric oxide signaling and cause vasodilation in both peripheral and pulmonary vessels. Endothelin receptor antagonists such as bosentan block endothelin-1, a potent vasoconstrictor and vascular remodeling mediator. Prostacyclin analogs further promote vasodilation and inhibit platelet aggregation. These drugs address the abnormal vascular tone and remodeling that limit blood flow in scleroderma.
Gastrointestinal medications are often used because smooth muscle dysfunction and connective tissue deposition can impair motility. Proton pump inhibitors reduce acid exposure from reflux caused by lower esophageal sphincter dysfunction. Prokinetic agents may be used to improve transit in the esophagus or stomach when motility is reduced. These treatments do not remove fibrosis, but they reduce the secondary injury caused by acid reflux, poor motility, and malabsorption.
Blood pressure and kidney-directed treatment is critical in scleroderma renal crisis. Angiotensin-converting enzyme inhibitors are the key therapy because they block the renin-angiotensin system, rapidly lowering the severe vasoconstriction that drives malignant hypertension and kidney ischemia. This treatment addresses the acute vascular pathology that can rapidly damage renal tissue and become life-threatening.
Procedures or Interventions
Procedures are used when medication alone cannot correct structural complications or when a specific organ injury has become advanced. In severe pulmonary arterial hypertension, right heart catheterization is often used to confirm the diagnosis and guide therapy. This is a diagnostic hemodynamic intervention rather than a treatment, but it is central to selecting drugs that alter pulmonary vascular resistance.
For advanced digital ischemia, procedures may be used to restore blood flow or remove damaged tissue. Surgical debridement or amputation can be necessary if tissue necrosis occurs after prolonged ischemia. In some cases, digital sympathectomy is performed to reduce sympathetic vasoconstriction in the affected arteries. By interrupting nerve-driven vasospasm, this procedure can improve circulation to threatened digits.
Oxygen therapy may be used in severe lung disease or pulmonary hypertension to improve oxygen delivery when gas exchange is impaired. While it does not reverse fibrosis, it compensates for the reduced transfer of oxygen across damaged alveolar tissue and can reduce strain on the heart.
In advanced cases of irreversible organ failure, transplantation may be considered. Lung transplantation can be used for end-stage interstitial lung disease or pulmonary hypertension when damage is too extensive for medical control. Transplantation replaces the diseased organ with one that has normal structure and function, but it does not remove the underlying autoimmune tendency, so long-term monitoring remains necessary.
Supportive or Long-Term Management Approaches
Long-term management is directed at preserving function and detecting organ involvement early. Because scleroderma can evolve gradually and affect multiple systems, repeated monitoring of lung function, kidney function, blood pressure, cardiac status, and skin involvement is a core part of care. This monitoring identifies physiologic change before it becomes clinically irreversible, allowing treatment to be adjusted when disease activity increases.
Rehabilitation and physical measures are important because fibrosis and vascular dysfunction can reduce range of motion, hand function, and tissue flexibility. Stretching and movement-based therapy help counter contracture formation by maintaining mechanical mobility across skin and joints. Hand care can reduce trauma to tissue with poor blood flow, and warming measures can lessen cold-induced vasospasm by reducing sympathetic vasoconstriction.
Management of reflux, nutrition, and swallowing function is also part of long-term care. Esophageal involvement can lead to impaired clearance of food and acid, so dietary modification and acid suppression are used to reduce mucosal injury. When motility is slow, nutritional status can be affected by poor intake or malabsorption, making follow-up important for maintaining body mass and tissue repair capacity.
Skin care and wound care support healing in areas where circulation is limited. Chronic ischemia slows tissue repair because oxygen and nutrients reach the tissue less effectively. Careful monitoring of ulcers and sores helps prevent infection and progression to necrosis. In this way, supportive care does not modify the immune process directly, but it limits the downstream consequences of vascular compromise and fibrosis.
Factors That Influence Treatment Choices
Treatment varies according to whether the disease is limited to the skin or involves internal organs. Diffuse cutaneous scleroderma tends to progress more rapidly and is more likely to affect the lungs, heart, and kidneys, so systemic immunosuppression is more often used early. Limited cutaneous disease may progress more slowly and may be managed with a greater emphasis on vascular and gastrointestinal symptoms unless organ involvement develops.
The stage of disease also matters. Early inflammatory disease is more likely to respond to immune-targeted therapy because the fibrotic process may still be evolving. Established fibrosis is less reversible, so treatment focuses more on slowing progression and preserving function than on expecting structural reversal. Organ-specific involvement changes the treatment plan as well. Lung disease may lead to antifibrotic or immunosuppressive therapy, whereas severe Raynaud phenomenon may require vasodilators and vascular interventions.
Age, cardiovascular status, kidney function, and other medical conditions influence drug selection because they alter how safely the body can tolerate treatment. More intensive immunosuppression may be limited by infection risk or reduced bone marrow reserve. Vasodilators may need to be selected carefully in people with low blood pressure or significant heart disease. Previous response to treatment also matters, because ongoing progression despite one approach may indicate the need to switch to another pathway-targeted drug.
Potential Risks or Limitations of Treatment
Most treatments for scleroderma are limited by the fact that they control disease activity better than they reverse established fibrosis. Once collagen is deposited and tissue architecture is altered, medications can slow further damage but often cannot restore normal structure. This is why early treatment matters biologically: the more active inflammatory and vascular phases are controlled, the less fixed fibrosis is likely to accumulate.
Immunosuppressive drugs carry risks related to broad immune inhibition. They can increase susceptibility to infection, suppress bone marrow function, and affect liver or kidney function depending on the agent. Because these effects arise from reduced immune surveillance or direct cellular toxicity, they require regular monitoring.
Vasodilators can cause low blood pressure, headaches, flushing, edema, or drug interactions. These effects stem from their action on vascular smooth muscle and systemic circulation. In patients with severe vascular disease, the benefit of improved perfusion must be balanced against reduced systemic pressure.
Antifibrotic agents may cause gastrointestinal side effects or liver enzyme abnormalities. Procedures such as debridement, sympathectomy, or transplantation have risks related to surgery, anesthesia, infection, rejection, or incomplete benefit if the underlying disease continues to act elsewhere in the body. Because scleroderma is systemic, treating one organ does not necessarily stop disease activity in another.
Conclusion
Scleroderma is treated by targeting the biological processes that drive the disease: immune activation, vascular dysfunction, and fibrosis. Medical therapy may suppress the immune system, improve blood flow, slow fibrotic signaling, or manage organ-specific complications. Procedures are used when structural damage, ischemia, or organ failure requires direct intervention. Long-term management focuses on monitoring and preserving function because the condition can affect multiple organs over time. The overall treatment strategy is therefore not a single therapy but a coordinated effort to reduce symptoms, slow progression, and limit the physiologic consequences of chronic immune-mediated tissue injury.